Ranbaxy Halts Shipments From Two Plants Already Blocked By U.S. FDA
This article was originally published in PharmAsia News
Ranbaxy Laboratories has stopped all shipments from two of its India plants that had been banned for exporting to the U.S., but had been allowed to continue to produce for India and other countries.
You may also be interested in...
A new report focused on the European market says that winning trust is the key to taking AI adoption to the next stage. That approach was praised by MedTech Europe CEO Serge Bernasconi.
As the transition period following the UK’s withdrawal from the European Union draws to a close, cosmetics industry stakeholders are following final trade negotiations while readying themselves for new regulatory complexities.
Purdue’s opioid settlement is making headlines for the size of the financial penalty. But the plan to re-imagine Purdue as a ‘public benefit company’ could have far-reaching significance for the industry – if it ever gets off the ground.